HCV-RNA eradication in antiviral treatment naive patients having HCV genotypes 1, 2 or 3 using ribavirin and interferon alpha combination therapy

摘要

Use of ribavirin and interferon alpha to prepare pharmaceutical compositions for treating antiviral treatment naive patient having chronic hepatitis C infection. The treatment is a combination therapy designed to eradicate detectable HCV-RNA. It involves using a therapeutically effective amount of ribavirin and a therapeutically effective amount of interferon-alpha for a period of from 20 up to 50 weeks.